Key Publications.

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Author

Kiladjian, JJ., Marin, F.F., Al-Ali, H.K. et al.

Publication Year

2024

Source

Ann Hematol (2024). DOI: 10.1007/s00277-024-05665-4

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Author

Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A

Publication Year

2023

Source

NEJM Evidence. 2023 May 23;2(6):EVIDoa2200335

PROUD-PV Study Group. Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b.

Author

Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H

Publication Year

2022

Source

Leukemia. 2022 May;36(5):1408-1411. DOI: 10.1038/s41375-022-01528-x

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Author

Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A

Publication Year

2021

Source

Lancet Haematol. 2021 Mar;8(3):e175-e184. DOI: 10.1016/S2352-3026(20)30373-2

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Author

Jäger R, Gisslinger H, Fuchs E, Bogner E, Milosevic Feenstra JD, Weinzierl J, Schischlik F, Gisslinger B, Schalling M, Zörer M, Krejcy K, Klade C, Kralovics R

Publication Year

2021

Source

Blood. 2021 Jan 21;137(3):387-391. DOI: 10.1182/blood.2020005792

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Author

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Hasselbalch HC, Kralovics R, Kiladjian JJ

Publication Year

2020

Source

Hemasphere. 2020 Oct 20;4(6):e485. DOI: 10.1097/HS9.0000000000000485

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Author

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ

Publication Year

2020

Source

PROUD-PV Study Group. Lancet Haematol. 2020 Mar;7(3):e196-e208. DOI: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Author

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ

Publication Year

2018

Source

Blood Cancer J. 2018 Oct 4;8(10):94. DOI: 10.1038/s41408-018-0133-0

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Author

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R

Publication Year

2015

Source

Blood. 2015 Oct 8;126(15):1762-9. DOI: 10.1182/blood-2015-04-637280

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Author

Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R

Publication Year

2015

Source

Am J Hematol. 2015 Apr;90(4):288-94. DOI: 10.1002/ajh.23928

Hemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.

Author

Gerges C, Montani D, Humbert M, Lang IM

Publication Year

2024

Source

European Respiratory Journal. 2024 Jan 1. DOI: 10.1183/13993003.02280-2023

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil - PubMed (nih.gov).

Author

Jansa P, Kopeć G, Torbicki A, Sadushi-Kolici R, Campean IA, Halank M, Simkova I, Steringer-Mascherbauer R, Salobir B, Klepetko W, Lindner J, Lang IM

Publication Year

2023

Source

Pulm Circ. 2023 Aug 21;13(3):e12274. doi: 10.1002/pul2.12274

Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.

Author

Steringer-Mascherbauer R, Maria L, Reinhold F, Elisabeth S, Charlotte H, Dagmar E, Uwe F, Josef A

Publication Year

2021

Source

J Cardiovasc Pharmacol. 2021 Jan 1;77(1):38-42. DOI: 10.1097/FJC.0000000000000933

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications.

Author

Steringer-Mascherbauer R, Lummersdorfer M, Függer R, Sigmund E, Huber C, Engleder D, Fröschl U, Aichinger J

Publication Year

2020

Source

Pulm Circ. 2020 Nov 30;10(4). DOI: 10.1177/2045894020970830

Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation.

Author

Zebedin-Brandl E, Themanns M, Kazemi Z, Nasrollahi-Shirazi S, Mussbacher M, Heyes E, Meissl K, Prchal-Murphy M, Strohmaier W, Krumpl G, Freissmuth M

Publication Year

2020

Source

J Mol Med (Berl). 2020 Feb;98(2):233-243. doi: 10.1007/s00109-019-01869-8. Epub 2019 Dec 24

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Author

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM

Publication Year

2019

Source

Lancet Respir Med. 2019 Mar;7(3):239-248

Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension.

Author

Schroeder L, Monno P, Unger M, Ackerl J, Shatilova O, Schmitt J, Dresbach T, Mueller A, Kipfmueller F

Publication Year

2023

Source

ESC Heart Fail. 2023 Feb;10(1):385-396. DOI: 10.1002/ehf2.14202

Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol.

Author

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Husch B

Publication Year

2022

Source

Clin Pharmacol Drug Dev. 2022 Mar;11(3):309-317. doi: 10.1002/cpdd.1025. Epub 2021 Oct 16. PMID: 34655181. DOI: 10.1002/cpdd.1025

Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.

Author

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J

Publication Year

2020

Source

BMC Pharmacol Toxicol. 2020 Nov 25;21(1):82. DOI: 10.1186/s40360-020-00462-x

Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.

Author

Stix G, Wolzt M, Domanovits H, Kadlecová P, Husch B, Trebs M, Hodisch J, Unger M, Krumpl G

Publication Year

2019

Source

Circ J. 2019 Dec 25;84(1):33-42. DOI: 10.1253/circj.CJ-19-0661

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.

Author

Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, Joannidis M, Heinz G, Cerny V, Dostál P, Siebers C, Guarracino F, Pratesi F, Biancofiore G, Girardis M, Kadlecova P, Bouvet O, Zörer M, Grohmann-Izay B, Krejcy K, Klade C, Krumpl G

Publication Year

2018

Source

Trials. 2018 Nov 19;19(1):637. doi: 10.1186/s13063-018-3024-6. PMID: 30454042; PMCID: PMC6245811. DOI: 10.1186/s13063-018-3024-6

Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.

Author

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, Husch B

Publication Year

2018

Source

J Cardiovasc Pharmacol. 2018 Mar;71(3):137-146. DOI: 10.1097/FJC.0000000000000554

Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites.

Author

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, Husch B

Publication Year

2017

Source

J Cardiovasc Pharmacol. 2017 Jul;70(1):42-51. DOI: 10.1097/FJC.0000000000000495

Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Author

Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J

Publication Year

2017

Source

Eur J Clin Pharmacol. 2017 Apr;73(4):417-428. DOI: 10.1007/s00228-016-2176-0

Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.

Author

Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J

Publication Year

2016

Source

Eur J Pharm Sci. 2016 Sep 20;92:64-73. DOI: 10.1016/j.ejps.2016.06.022

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Author

Krumpl G, Ulč I, Trebs M, Hodisch J, Kadlecová P, Husch B

Publication Year

2020

Source

Cureus. 2020 Dec 22;12(12):e12217. DOI: 10.7759/cureus.12217

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Author

Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C

Publication Year

2019

Source

Br J Haematol. 2019 May;185(4):691-700. DOI: 10.1111/bjh.15824

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

Author

Petrides PE, Schoergenhofer C, Widmann R, Jilma B, Klade CS

Publication Year

2018

Source

Clin Pharmacol Drug Dev. 2018 Feb;7(2):123-131. DOI: 10.1002/cpdd.34002.008

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Author

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE

Publication Year

2013

Source

Blood. 2013 Mar 7;121(10):1720-8. DOI: 10.1182/blood-2012-07-443770

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Author

Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R

Publication Year

2009

Source

R. Clin Ther. 2009 Feb;31 (2):386-98. DOI: 10.1016/j.clinthera.2009

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

Author

Steurer M, Gasti G, Jedrzejczak WW, Pytlik R, Lin W, SchlogI E, Gisslinger H. Cancer

Publication Year

2004

Source

Cancer. 2004 Nov 15;101 (10):2239-46. DOI: 10.1002/cncr.20646

Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.

Author

Peball M, Krismer F, Knaus HG, Djamshidian A, Werkmann M, Carbone F, Ellmerer P, Heim B, Marini K, Valent D, Goebel G, Ulmer H, Stockner H, Wenning GK, Stolz R, Krejcy K, Poewe W, Seppi K

Publication Year

2020

Source

Collaborators of the Parkinson's Disease Working Group Innsbruck. Ann Neurol. 2020 Oct;88(4):712-722

Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).

Author

Peball M, Werkmann M, Ellmerer P, Stolz R, Valent D, Knaus HG, Ulmer H, Djamshidian A, Poewe W, Seppi K

Publication Year

2019

Source

J Neural Transm (Vienna). 2019 Aug;126(8):1061-1072

Needs. Science. Trust.

As a privately owned company, AOP Health is devoted to long-term commitment, high quality, and continuity. For a small number of very special diseases the company is sole supplier of some key therapeutic agents throughout the world.